BackGuanhao Biotech ,Ltd. Overview

Guanhao Biotech ,Ltd. EBIT

Guanhao Biotech ,Ltd.'s EBIT is $12M, below the Healthcare sector average of $1.9T.

Get informed when a big investor buys or sells

+ Follow

Quarterly EBIT

$2.30M
↓ 71.96% YoY

As of Sep 30, 2026

Annual EBIT (TTM)

$12.37M
↓ 61.55% YoY

Trailing 12 months ending Sep 30, 2026

Average EBIT (Comparison Companies)

EBIT History

EBIT Comparison

Annual EBIT Growth Rate (%)

Annual EBIT Growth (Absolute)

Guanhao Biotech ,Ltd. (300238.SZ) FAQ

The latest EBIT for 300238.SZ is $12M as of September 2026. That compares with $32M in the prior-year period — down 61.5% year over year. That is below the Healthcare sector average of $1.9T. Investors often review this figure alongside Guanhao Biotech ,Ltd.'s historical trend and sector peers before judging valuation or financial health.

Over the past year, 300238.SZ's EBIT moved from $32M to $12M — a 61.5% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Guanhao Biotech ,Ltd.'s operating scale or balance-sheet position.

Against Healthcare companies, 300238.SZ currently prints $12M for EBIT, while the sector average sits near $1.9T. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Guanhao Biotech ,Ltd.'s growth, margins, and balance sheet.

A EBIT figure of $12M for 300238.SZ is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $1.9T. Explore the charts below for those layers of context.

After noting 300238.SZ's EBIT ($12M), review year-over-year change from $32M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.